[go: up one dir, main page]

PT90660A - Processo para a preparacao de composicoes farmaceuticas compreendendo a associacao de substancias que libertam tnf (factor de necrose tumoral)e de inibidores de tnf - Google Patents

Processo para a preparacao de composicoes farmaceuticas compreendendo a associacao de substancias que libertam tnf (factor de necrose tumoral)e de inibidores de tnf

Info

Publication number
PT90660A
PT90660A PT90660A PT9066089A PT90660A PT 90660 A PT90660 A PT 90660A PT 90660 A PT90660 A PT 90660A PT 9066089 A PT9066089 A PT 9066089A PT 90660 A PT90660 A PT 90660A
Authority
PT
Portugal
Prior art keywords
tnf
preparation
combination
pharmaceutical compositions
substances free
Prior art date
Application number
PT90660A
Other languages
English (en)
Other versions
PT90660B (pt
Inventor
Heinz Haenel
Elmar Schrinner
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PT90660A publication Critical patent/PT90660A/pt
Publication of PT90660B publication Critical patent/PT90660B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT90660A 1988-05-27 1989-05-24 Processo para a preparacao de composicoes farmaceuticas compreendendo a associacao de substancias que libertam tnf (factor de necrose tumoral)e de inibidores de tnf PT90660B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3817955A DE3817955A1 (de) 1988-05-27 1988-05-27 Tnf-inhibitor enthaltendes arzneimittel

Publications (2)

Publication Number Publication Date
PT90660A true PT90660A (pt) 1989-11-30
PT90660B PT90660B (pt) 1994-10-31

Family

ID=6355195

Family Applications (1)

Application Number Title Priority Date Filing Date
PT90660A PT90660B (pt) 1988-05-27 1989-05-24 Processo para a preparacao de composicoes farmaceuticas compreendendo a associacao de substancias que libertam tnf (factor de necrose tumoral)e de inibidores de tnf

Country Status (9)

Country Link
US (1) US5118500A (pt)
EP (1) EP0344586B1 (pt)
JP (1) JP3140021B2 (pt)
AT (1) ATE135225T1 (pt)
DE (2) DE3817955A1 (pt)
DK (1) DK258989A (pt)
ES (1) ES2086309T3 (pt)
GR (1) GR3020101T3 (pt)
PT (1) PT90660B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5196429A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5196430A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
DE4019571A1 (de) * 1990-06-20 1992-01-02 Hoechst Ag Pharmazeutische kombinationspraeparate enthaltend cephalosporin- und xanthinderivate und deren verwendung
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
WO1992007566A2 (en) * 1990-11-01 1992-05-14 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
IL100088A (en) * 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
EP0493682A3 (en) * 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
WO1993001211A1 (en) * 1991-07-05 1993-01-21 Peptide Technology Limited Peptide which abrogates tnf and/or lps toxicity
ES2038546B1 (es) * 1991-11-08 1994-02-16 Andromaco Lab Procedimiento de obtencion de un producto de naturaleza polipeptidica con actividad inhibidora de la hiperproduccion del factor de necrosis tumoral.
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
US5567704A (en) * 1992-03-04 1996-10-22 Cell Therapeutics, Inc. R-enatiomerically pure hydroxylated xanthine compounds to treat baldness
DK0584347T3 (da) * 1992-03-04 2003-02-24 Cell Therapeutics Inc Enantiomere hydroxylerede xanthinforbindelser
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
PL173978B1 (pl) * 1992-07-13 1998-05-29 Nika Health Products Ltd Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5795897A (en) * 1992-11-18 1998-08-18 Cell Therapeutics, Inc. Oxohexyl methylxanthine compounds
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
WO1994016704A1 (en) * 1993-01-19 1994-08-04 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
AU1090795A (en) * 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
CA2183562A1 (en) * 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6010711A (en) * 1996-01-26 2000-01-04 University Of Rochester Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
EP1712239A3 (en) * 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
WO2005094879A2 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human ox40l (cd 134l)
MX2021005847A (es) 2018-11-19 2021-09-23 Univ Texas Gen suicida.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines

Also Published As

Publication number Publication date
ATE135225T1 (de) 1996-03-15
JP3140021B2 (ja) 2001-03-05
DK258989A (da) 1989-11-28
DE3817955A1 (de) 1989-11-30
ES2086309T3 (es) 1996-07-01
JPH0219327A (ja) 1990-01-23
GR3020101T3 (en) 1996-08-31
PT90660B (pt) 1994-10-31
EP0344586A2 (de) 1989-12-06
EP0344586B1 (de) 1996-03-13
US5118500A (en) 1992-06-02
EP0344586A3 (en) 1990-05-16
DE58909621D1 (de) 1996-04-18
DK258989D0 (da) 1989-05-26

Similar Documents

Publication Publication Date Title
PT90660A (pt) Processo para a preparacao de composicoes farmaceuticas compreendendo a associacao de substancias que libertam tnf (factor de necrose tumoral)e de inibidores de tnf
SE8503762L (sv) Analgetiska och anti-inflammatoriska kompositioner innefattande xantiner och forfarande for anvendning av dessa
ES2080307T3 (es) Composiciones farmaceuticas.
MX9202289A (es) Nuevos derivados de tiopiranopirrol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9206503A (es) Nuevos derivados de lupano, proceso para su preparacion y composicion farmaceutica que los contiene.
MX9206938A (es) Nuevos derivados peptidos, proceso para su preparacion y preparacion farmaceutica que comprende tales derivados.
MX9206306A (es) Peptidos, procedimiento para su produccion y composicion farmaceutica que los contiene.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
MX9200374A (es) Nuevos esteres esteroides, procedimiento para su preparacion y preparacion farmaceutica que los contiene.
MX9203114A (es) Nuevos derivados morfolino de daunorubicina y doxorubicina y composiciones farmaceuticas que los contienen.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2051678T1 (es) Derivados de 5-oxo-l-prolina y uso farmaceutico de los mismos.
MX9202982A (es) Derivados de los acidos quinolon - y naftiridon - carboxilicos, procedimiento para su obtencion y medicamentos que los contienen.
MX9201058A (es) Derivados ciclicos de cetal, procedimiento para supreparacion y composicion farmaceutica que los contiene.
MX9201295A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contienen.
MX9202152A (es) Derivados del indol, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9201847A (es) Derivados heterociclicos de antiserotoninas, procedimiento para su preparacion y medicamentos que los contienen.
ATE69164T1 (de) Arzneimittel zur behandlung von uraemie.
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
MX9204395A (es) Derivados de 3-desoxi-manosamina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
MX9207269A (es) Bencimidazoles substituidos, proceso para su preparacion y composiciones farmaceuticas que los contienen.
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
MX9100886A (es) Activador de plasminogeno hibrido,procedimiento para su preparacion y composiciones farmaceuticas que lo contienen
MX9204648A (es) Nuevos derivados de esteres, procedimiento para su preparacion y composicion farmaceutica que los contiene.

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19940407

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19991031